Arca
Skip to content
Tools
Tools

Label Changes: Olumiant (baricitinib)

A drug's label (its prescribing information) is revised many times after approval: new warnings, new uses, new doses. DailyMed keeps every version. Pick a drug to see them all and what changed between any two.

Every version of the Olumiant label DailyMed has published, from Eli Lilly and Company, and what changed between any two of them, section by section. Current label on DailyMed.

  • Versions on DailyMed: 20
  • Sections changed, version 31 to 32: 10, Including the boxed warning

What changed from version 31 to version 32

Oct 9, 2026 to Oct 22, 2026, as published on DailyMed. Added text is underlined in green, removed text struck through in red.
  1. Boxed warningChanged · 50 words added, 12 removed
  2. Indications and usageChanged · 1 word added, 2 removed
  3. Dosage and administrationChanged · 1 word added, 1 removed
  4. Warnings and precautionsChanged · 256 words added, 129 removed
  5. Adverse reactionsChanged · 4 words added, 4 removed
  6. Clinical pharmacologyChanged · 5 words added, 9 removed
  7. Clinical studiesChanged · 481 words added, 3 removed
  8. How suppliedChanged · 6 removed
  9. Patient counseling informationChanged · 78 words added, 50 removed
  10. Medication guideChanged · 10 words added, 31 removed

Boxed warning

Changed50 words added, 12 removed
14 unchanged lines
MAJOR ADVERSE CARDIOVASCULAR EVENTS
MACE (defined as cardiovascular death, myocardial infarction, and stroke) may occur in patients treated with OLUMIANT. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)].
THROMBOSIS
Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. In two studies of patients with RA with an increased risk of venous thrombosis, a higher rate of venous thrombosis was observed in patients treated with OLUMIANT compared to patients treated with TNF blockers. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OLUMIANT in patients at risk. Patients with symptoms of thrombosis should discontinue OLUMIANT and be promptly evaluated. [see Warnings and Precautions (5.5)].

Indications and usage

Changed1 word added, 2 removed
1 unchanged line
1.1 Moderately to Severely Active Rheumatoid Arthritis
OLUMIANT® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adult patientsadults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.
5 unchanged lines

Dosage and administration

Changed1 word added, 1 removed
6 unchanged lines
Monitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.9)].
Baseline hepatic and renal function – Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.56) and Warnings and Precautions (5.9)].
In patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.10)].
91 unchanged lines

Warnings and precautions

Changed256 words added, 129 removed
1 unchanged line
5.1 Serious Infections
Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:
16 unchanged lines
5.3 Malignancy and Lymphoproliferative Disorders
Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)].
Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)]. In the integrated analysis of two randomized controlled studies (RA Safety Studies 1 and 2) [see Clinical Studies (14.4)], the incidence rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was 1.06 per 100 patient-years in subjects treated with OLUMIANT 2 mg/day and 4 mg/day combined, and 0.83 per 100 patient-years in subjects treated with TNF blockers.
In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.
3 unchanged lines
5.4 Major Adverse Cardiovascular Events
Major adverse cardiovascular events (MACE) may occur in patients treated with OLUMIANT. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.
5.5 Thrombosis
Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.
Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), was observed at an increased incidence in patients treated with OLUMIANT compared to patients treated with placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies in patients treated with OLUMIANT. Many of these adverse events were serious and some resulted in death.
In a planned integrated analysis of two randomized controlled studies (RA Safety Studies 1 and 2) in RA subjects with increased risk of venous thromboembolic events (VTE), a higher incidence rate of VTE, including DVT and PE, was observed in subjects treated with OLUMIANT 2 mg/day or OLUMIANT 4 mg/day compared to those treated with TNF blockers [see Clinical Studies (14.4)]. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.
If clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.
5.6 Hypersensitivity Reactions
Reactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].
20 unchanged lines

Adverse reactions

Changed4 words added, 4 removed
89 unchanged lines
c Acne includes: acne and dermatitis acneiform.
d Hyperlipidemia includes: hyperlipidaemiahyperlipidemia, hypercholesterolaemiahypercholesterolemia, hypertriglyceridaemiahypertriglyceridemia, dyslipidaemiadyslipidemia, lipids increased, low density lipoprotein increased, blood cholesterol increased, and blood triglycerides increased.
e UTI includes: cystitis, urinary tract infection, white blood cells urine positive, urinary tract infection bacterial, and pyelonephritis.
36 unchanged lines

Clinical pharmacology

Changed5 words added, 9 removed
5 unchanged lines
Baricitinib inhibition of IL-6 induced STAT3 phosphorylation – Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.
Immunoglobulins – Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with OLUMIANT, and remained stable through at least 52 weeks. For most patientssubjects, changes in immunoglobulins occurred within the normal reference range.
C-reactive protein – In patientssubjects with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.
Cardiac Electrophysiology – At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.
5 unchanged lines
Moderately to Severely Active Rheumatoid Arthritis and Severe Alopecia Areata: The total body clearance of baricitinib is 8.9 L/h in subjects with moderately to severely active rheumatoid arthritis and 11 L/h in subjects with severe alopecia areata. Elimination half-life in subjects with moderately to severely active rheumatoid arthritis and severe alopecia areata is approximately 12 to 16 hours.
COVID-19: The total body clearance and half-life of baricitinib is 14.2 L/h and 10.8 hours, respectively, in patientssubjects with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.
Metabolism – Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.
Excretion – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominatelypredominantly as unchanged drug in urine (69%) and feces (15%).
Specific Populations
18 unchanged lines
Potential for Other Drugs to Influence the PK of Baricitinib
In vitro studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicinrifampin (CYP3A inducer).
In vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC0-∞ with no effect on Cmax and tmax [see Dosage and Administration (2.2, 2.3, 2.7) and Drug Interactions (7.1)]. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.
Exposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.
3 unchanged lines

Clinical studies

Changed481 words added, 3 removed
5 unchanged lines
The results from the dose-ranging studies are shown in Table 11. In dose-ranging Study RA-1, the observed ACR response was similar for baricitinib 1 and 2 mg daily and for baricitinib 4 and 8 mg daily, with the highest response for baricitinib 8 mg daily. In dose-ranging Study RA-2, there was not a clear trend of dose response, with similar response rates for 1 mg and 4 mg and 2 mg and 8 mg.
Table 11: Proportion of PatientsSubjects with ACR20 Response at Week 12 in Dose-Ranging RA Studies
| % ACR20 Responders
13 unchanged lines
a Subjects who were rescued or discontinued treatment were considered as non-responders in the analyses.
b 95% confidence interval (CI) for the difference (∆) in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).
| Percent of Subjects
45 unchanged lines
Week 12 | 17.2 (19.3) | 8.6 (14.6) | 19.9 (23.0) | 13.5 (20.1)
Figure 4: Percent of RA Subjects AchievingWho Achieved ACR20 in Study RA-4
Physical Function Response
26 unchanged lines
COVID II
A randomized, double-blind, placebo-controlled clinical trial (NCT04421027) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib 4mg4 mg once daily (n = 764) with placebo (n = 761) for 14 days or hospital discharge, whichever came first. Subjects could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals, corticosteroids, and/or azithromycin. In this study prophylaxis for venous thromboembolic event (VTE) was required for all subjects unless contraindicated.
The most frequently used therapies at baseline were:
55 unchanged lines
95% to 100% Scalp Hair Loss N SALT ≤20 | 55 2% | 55 15% | 54 28%
14.4 Safety Studies
RA Safety Study 1; NCT03915964 and RA Safety Study 2; NCT04086745 were two randomized, open-label, active-controlled trials designed to evaluate the safety of two OLUMIANT dosing regimens, 2 mg once daily (N=1219) and 4 mg once daily (2 times the recommended dosage for the treatment of moderately to severely active RA) (N=1214), versus the TNF blocker comparator (N=1207) in subjects with moderately to severely active RA who had increased risk of VTE. The integrated analysis of RA Safety Study 1 and 2 trials compared the risk of VTE between the combined OLUMIANT dosing regimens and TNF blocker comparator. The primary endpoint was the hazard ratio of combined OLUMIANT dosing regimens versus the TNF blocker control for the risk of blinded, independently adjudicated VTE (including DVT and PE).
The study population was selected for presenting an increased VTE risk based on a history of VTE, age ≥60 years, BMI ≥30 kg/m², or age 50 to <60 years with a BMI 25 to <30 kg/m². The mean age of the population was 60 years, the mean BMI was 31 kg/m², and 4% had a history of VTE. Most subjects were female (78%) and White (91%). Subjects had a diagnosis of RA for a mean of 8.7 years, and a median swollen and tender joint count of 9 and 13 respectively.
At or after Week 52, 32% of subjects who were initially treated with OLUMIANT 2 mg/day received OLUMIANT 4 mg/day. The median exposure to OLUMIANT 2 mg/day, 4 mg/day, and TNF blocker were 1.5 years, 3.8 years, and 3.7 years respectively. A total of 47% of subjects treated with OLUMIANT and 46% treated with TNF blocker completed these Safety Studies.
Table 18 shows the study results for VTE, DVT, and PE per treatment group in RA Safety Studies 1 and 2. There was an increased risk of VTE associated with both OLUMIANT dosages compared to TNF blocker.
Table 18: Results of the Integrated Analysis of VTEs in RA Safety Studies 1 and 2
| OLUMIANT 2 mg/day N=1219 PY=2787 | OLUMIANT 4 mg/day N=1214 PY=3901 | TNF Blocker N=1207 PY=3830
Abbreviations: VTE=venous thromboembolism; DVT=deep vein thrombosis; PE=pulmonary embolism; HR = hazard ratio; PY = patient years; n = number of patients with events; IR = incidence rate per 100 PY.
a Subjects with a VTE counted once for at least one DVT and/or PE and/or other peripheral venous thrombosis.
VTE, n [IR]a | 25 [0.88] | 33 [0.83] | 20 [0.51]
HR (95% CI) | 1.70 (0.94, 3.08) | 1.69 (0.97, 2.94) |
DVT, n [IR] | 13 [0.46] | 14 [0.35] | 11 [0.28]
PE, n [IR] | 14 [0.49] | 20 [0.50] | 10 [0.25]

How supplied

Changed6 removed
11 unchanged lines
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Keep out of reach of children.

Patient counseling information

Changed78 words added, 50 removed
1 unchanged line
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Serious Infections
Infections
Inform patients that they may be more likely to develop infections when taking OLUMIANT. Instruct patients to tell their healthcare provider if they develop any signs or symptoms of an infection [see Warnings and Precautions (5.1)].
5 unchanged lines
Thrombosis
Advise patients that events of DVT and PE have been reported in clinical studies with OLUMIANT. Instruct patients to seek immediate medical attention if they develop any signs or symptoms of a DVT or PE [see Warnings and Precautions (5.5)].
Advise patients that OLUMIANT may increase their risk of thrombosis. Instruct patients to seek immediate medical attention if they develop any signs or symptoms of a thrombosis (sudden shortness of breath, chest pain worsened with breathing, swelling of leg or arm, leg pain or tenderness, red or discolored skin in the affected leg or arm) [see Warnings and Precautions (5.5)].
Hypersensitivity
13 unchanged lines
Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
www.olumiant.com
For more information, see www.olumiant.com
Copyright © 2018, 2026, Eli Lilly and Company. All rights reserved.
Pat.: www.lilly.com/patents
OLM-0009-USPI-20260925
OLM-0010-USPI-20261009

Medication guide

Changed10 words added, 31 removed
This Medication Guide has been approved by the U.S. Food and Drug Administration. | Revised: 0910/2026
MEDICATION GUIDE OLUMIANT ® (O-loo-me-ant) (baricitinib) tablets, for oral use
4 unchanged lines
4. Increased risk of major cardiovascular events such as heart attack, stroke or death in people 50 years of age and older who have at least 1 heart disease (cardiovascular) risk factor and taking a medicine in the class of medicines called JAK inhibitors, especially if you are a current or past smoker. Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with OLUMIANT, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech
5. Blood Clots. Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) and arteries (arterial thrombosis) can happen in some people during treatment with OLUMIANT. This may be life-threatening and cause death. Blood clots in the veins of the legs (deep vein thrombosis, DVT) and lungs (pulmonary embolism, PE) have happened more often in people who are 50 years of age and older and with at least 1 heart disease (cardiovascular)increased risk factor taking a medicine in the class of medicines called Janusblood kinaseclots (JAK)with inhibitorsOLUMIANT. Tell your healthcare provider if you have had blood clots in the veins of your legs or lungs in the past. Stop taking OLUMIANT and tell your healthcare provider or get emergency help right away if you get any signs and symptoms of blood clots during treatment with OLUMIANT, including: swelling, pain or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.
6. Allergic Reactions. Symptoms such as rash (hives), trouble breathing, feeling faint or dizzy, or swelling of your lips, tongue, or throat, that may mean you are having an allergic reaction have been seen in people taking OLUMIANT. Some of these reactions were serious. If any of these symptoms occur during treatment with OLUMIANT, stop taking OLUMIANT and get emergency help right away.
18 unchanged lines
What are the ingredients in OLUMIANT? Active ingredient: baricitinib Inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, titanium dioxide. OLUMIANT is a registered trademark of Eli Lilly and Company. Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA Copyright © 2018, 2026, Eli Lilly and Company. All rights reserved. For more information, call 1-800-545-5979 or go to the following website: www.olumiant.com.
OLM-0007-MG-20260925
OLM-0008-MG-20261009

Unchanged: Dosage forms and strengths, Contraindications, Drug interactions, Use in specific populations, Overdosage, Description, Nonclinical toxicology, PACKAGE LABEL – OLUMIANT 2 mg 30ct Bottle, PACKAGE LABEL – OLUMIANT 1 mg 30ct Bottle, PACKAGE LABEL – OLUMIANT 4 mg 30ct Bottle.

Every version

20 versions of set 866e9f35-9035-4581-a4b1-75a621ab55cf, newest first.

Read an SPL file

Open an SPL label file

Drop a Structured Product Labeling .xml file, or the .zip DailyMed downloads, to read it as a label. It is read in this browser tab and not uploaded.

Read in this browser tab; nothing is uploaded.

Versions and label text from DailyMed's SPL web services; a version's text is read from its SPL file, so it matches what DailyMed shows. Recent safety-related changes from FDA's Safety-related Labeling Changes database, which covers NDAs and CDER biologics, not generics. Lists refresh daily. DailyMed, National Library of Medicine

About label change history

How to read a comparison

Sections that changed come first, in the order a reviewer reads a label: boxed warning, recent major changes, indications, dosage, contraindications, warnings and precautions, adverse reactions, then the rest. Each shows the changed lines with one unchanged line either side; longer unchanged stretches are folded into a count. Table rows read left to right with cells separated by a bar.

The comparison covers the label text. Images, product data (NDC codes, ingredients, packaging) and formatting are not compared.

Which label is shown

A drug can have several labels: one per brand-name application (Ozempic, Wegovy and Rybelsus are three), and copies from repackagers. For each NDA or BLA the page takes the DailyMed set with the most versions, which is the application holder's. Generic labels are left out; they follow the brand's label.

Frequently asked questions

Where do the versions come from?
DailyMed, the National Library of Medicine's library of labels in Structured Product Labeling (SPL) format. Each time a company submits a revised label, DailyMed publishes it as a new version of the same set and keeps the old ones.
Is a new version a new FDA approval?
Not always. Companies also submit new versions for changes that need no FDA approval first, such as a new address, a new package size or a corrected typo. Safety changes FDA approved are listed in its Safety-related Labeling Changes database, linked below.
Why does the published date differ from the label's revised date?
The published date is when DailyMed posted the version. The label's own revised date, at the end of the highlights, is when the company revised the text, usually a few days to weeks earlier.
How is the comparison made?
Each section is matched by its standard LOINC code, then split into headings, paragraphs, list items and table rows. Lines are aligned with a longest-common-subsequence diff; a removed and an added line that share at least half their words are shown as one edited line with the changed words marked. Curly quotes, dash styles and spacing are ignored.
Is my SPL file uploaded?
No. A file you drop on this page is read in your browser tab and never sent to Arca.
Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.